International Delphi consensus on radical thoracic re-irradiation for non-small cell lung cancer (NSCLC)
Authors
Rulach, R.Guckenberger, M.
De Ruysscher, D
Palma, D.
Louie, A.
Ball, D.
Hanna, G.
Siva, S.
Salem, Ahmed
Videtic, G.
Dahele, M.
Moghanaki, D.
Franks, K.
Harrow, S.
Affiliation
The Beatson West of Scotland Cancer Centre, Glasgow/GB,Issue Date
2021
Metadata
Show full item recordAbstract
Introduction: Local recurrence or second lung primaries are common indications for radical thoracic re-irradiation (re-RT), affecting approximately 700 patients in the UK annually. Re-RT is usually the only suitable curative-intent treatment but prospective evidence on toxicity, dose constraints, and optimal treatment technique is lacking. We performed a Delphi process to identify areas of consensus in re-RT for NSCLC. Methods: An international panel of 15 radiation oncologists specialising in lung cancer participated in an initial survey on 23/09/2019 to capture their definition of re-RT, suitable patients, re-RT technique and dose constraints used. The most common responses to questions from the first survey were used to make statements which participants voted on in subsequent rounds using a 5-point Likert scale. Consensus was achieved once 75% of participants agreed with a statement. For the statements which did not reach consensus, respondents provided additional evidence/ comments to refine them. In total, four surveys were performed using a web-based survey programme. Results: All respondents completed three rounds of the survey, with the final round currently in progress. Consensus was achieved within two rounds regarding re-RT indications, patient eligibility and work-up (Table 1). In addition, agreementwas reached to use stereotactic ablative body radiotherapy (SABR) if possible for re-RT. Dose constraints, due to the lack of supportive data, required three rounds to develop agreement. Several volumetric lung constraints were suggested, but due to post-radiotherapy fibrosis, it was concluded that there was insufficient evidence to form recommendations (Table 2). Areas of controversy were how much overlap was significant when performing re-RT, what were the minimum lung function requirements and the minimum safe interval between treatments. Conclusion: This Delphi process with international experts has developed key recommendations on the criteria for suitable re-RT patients, dose constraints and preferred technique. These statements can be used to develop prospective trials to provide better evidence for re-RT.Citation
Rulach R, Guckenberger M, De Ruysscher D, Palma D, Louie A, Ball D, et al. P05.02 International Delphi Consensus on Radical Thoracic Re-Irradiation for Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 2021 Mar;16(3):S266–7.Journal
Journal of Thoracic OncologyDOI
10.1016/j.jtho.2021.01.393Additional Links
https://dx.doi.org/10.1016/j.jtho.2021.01.393Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.jtho.2021.01.393